To determine if ruxolitinib affected the other activation markers, IL10 transcription in CLL cells in response to resiquimod with (2S) or without (S) IL-2 was measured at 4 and 24 h (Figure 3A). The gene discussed is IL2; the disease is B-cell chronic lymphocytic leukemia.